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The amplification of putative oncogenes is a common finding within the genome of various cancer types.
Identification and further targeting of specific junction sites within the sequence of genomic amplicons (amplicon
fusion sites, AFS) by PCR (AFS-PCR) is suitable for quantification of minimal residual disease (MRD). This approach
has recently been developed and described for MYCN amplified neuroblastomas. To compare AFS-PCR directly to
routinely used MRD diagnostic strategies, we mapped the amplified genomic regions (ampGR) of an
iAMP21-amplicon in high resolution of a patient with acute lymphoblastic leukemia (ALL). Successfully, we
established AFS-PCR covering junction sites between ampGR within the iAMP21-amplicon. Quantification of MRD
by AFS-PCR was directly comparable to IgH/TCR based real time quantitative PCR and fluorescence activated cell
sorting (FACS) analysis in consecutive bone marrow (BM) specimens. Our data give an additional proof of concept
of AFS-PCR for quantification of MRD. The method could be taken into account for ALL patients with genomic
amplifications as alternative MRD diagnostic, if no or qualitatively poor Ig/TCR-PCRs are available.Background
Recently, we described a strategy for developing tumor
cell specific PCRs for MYCN amplified neuroblastomas,
using junction sites (amplicon fusion sites, AFS) of amp-
lified genomic regions (ampGR) as template (AFS-PCR)
[1]. All ampGR and thus, all AFS identified were ab-
solute tumor cell specific and unique for each patient.
AFS-PCR was highly sensitive and uncovered one tumor
cell out of 106 - 107 control cells. We concluded this
method is suitable for MRD quantification of MYCN
amplified neuroblastoma. We furthermore hypothesized
AFS-PCR might not only be limited to neuroblastoma,
but transferable to other cancer types, provided that the
individual tumor cells harbour ampGR.* Correspondence: axel.weber@humangenetik.med.uni-giessen.de
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reproduction in any medium, provided the orThe detection and quantification of minimal amounts
of residual or recurrent leukemic blasts significantly im-
proved therapy management for adult and childhood
acute lymphoblastic leukemia (ALL) patients [2-4]. Rou-
tinely, rearrangements in immunoglobulin-chain (Ig) or
T-cell receptor genes (TCR) serve as template for the
design of tumor cell specific PCRs (Ig/TCR-PCR) [4-7].
Amplification of a part of the long arm of chromosome
21 including the AML1/RUNX1 gene (iAMP21) occurs
in 1-2% of ALL [8,9].
Bone marrow specimens from initial diagnosis and
subsequent time points of an ALL patient with iAMP21
were used to directly compare AFS-PCR to routinely used
MRD diagnostic strategies and to give additional proof of
concept for AFS-PCR as a method for tumor cell detec-
tion, not only for neuroblastoma.Results
Multiple copies of AML1/RUNX1 had been identified
by fluorescence-in-situ-hybridization (FISH) in a 9 yearLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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confirmed AML1/RUNX1 to be part of a large ampli-
fied genomic region of chromomosome 21 (iAMP21)
and excluded coamplified regions or additional ampGR on
other chromosomes by whole genome Array (Affymetrix
Cytogenetics Whole-Genome 2.7M Array) (Figure 1a). Be-
sides iAMP21, several deletions were identified, with most
relevant mapping to chromosomes 7p12.1-2 (including
IKZF1), 11q23.3 (disrupting MLL), 12q13.12 and 12q24.11.Figure 1 Mapping of the ampGR on chromosome 21 and identificatio
corresponding data of the Affymetrix whole genome array. The amplified g
Data is presented as Log2-ratios of internal normalized signal intesities. (b)
number for each printed oligonucleotide are presented as fluorescent inten
labelled reference-DNA (healthy human female) (Log2-ratio). The mean sign
the SignalMap-Software and is indicated by the red line. The ampGR is hig
amplicon. AmpGR are subsequently joined together in head-to-head and t
PCR are displayed as open or filled squares. (d) Chromatogram of the sequ
(e) Chromatograms of the sequenced junction sites of the tail-to-tail AFS-P(The deleted regions are quoted in detail in the Additional
file 1: Table S1.) Exact mapping of the iAMP21 ampGR
borders telomeric and centromeric to AML1 was per-
formed by high resolution Tiling-Array (HR-TA) of chro-
mosome 21 (Human-CGH-385K-Chromosome-21 Tiling
Array (Roche, NimbleGen)) (Figure 1b). Based on the ar-
ray data the centromeric border of the iAMP21 ampGR
was estimated between bases 34.613.680 and 34.615.721
(genomic annotation: GRCh37/hg19) and the telomericn of the AFS sequences. (a) Ideogram of chromosome 21 and
enomic region (ampGR) of chromosome 21 is highlighted in green.
Data of the high resolution tiling array (NimbleGen). The relative copy
sities of the Cy5 labelled test-DNA (cell lines) normalized to the Cy3
al intensity value of the continuous genomic region was calculated by
hlighted in green. (c) Model of the architecture of the AML1/RUNX1
ail-to-tail orientation, resulting in tumor cell specific AFS. Primer for
enced junction site of the head-to-head AFS-PCR-amplimer.
CR-amplimer.
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41.327.034. Overall, the ampGR covered 6.7Mb of ge-
nomic sequence. A list of amplified genes within the des-
cribed region is given in Additional file 1: Table S1.
The first and the last 1000 bp of the amplified sequence
of the iAMP21 were virtually fused to simulate junction
sites between the subsequent copies of the ampGR. There-
by, we took all possible junction sites into account
resulting from either head-to-tail or head-to-head and
tail-to-tail orientation of the subsequent ampGR sequen-
ces. The junction site bridging AFS-PCRs were designed
as previously described [1]. Interestingly the ampGR with-
in the iAMP21-amplicon were found exclusively arranged
head-to-head and tail-to-tail (Figure 1c), in contrast to the
investigated MYCN-amplicons in primary neuroblasto-
mas, in which all ampGR had been found in head-to-tail
orientation [1]. Using different pairs of primer, two diffe-
rent tail-to-tail orientated AFS were identified. Although
the ampGR were joined either in head-to-head or in tail-
to-tail orientation, the junction sites were not found to be
direct mirror planes at the single base-pair level. The sub-
sequently joined ampGR showed different extents to their
borders of about 745bp at the head-to-head junction and
880bp and 175bp, respectively at the tail-to-tail junctions.
We found two additional bases (CA) inserted in the
centromeric head-to-head AFS between the subsequent
copies of the ampGR (Figure 1d), and four additional
bases (TCCA) inserted in one of the two telomeric
tail-to-tail AFS between the subsequent copies of the
ampGR (Figure 1e). The second telomeric tail-to-tailFigure 2 Comparison of MRD values to different time points during t
AFS-PCR. (a) Calculated tumor cell numbers within the bone marrow from
(b) Calculated tumor cell numbers within the bone marrow from the day of
day-533 respectively. For AFS-PCR tumor cell contents of the different bone
method. Each PCR was performed in triplicate. Mean values and standard deAFS identified was a direct fusion of two subsequent
ampGR without additional inserted nucleotides.
Because of the close proximity of the two different
tail-to-tail AFS, it was not possible to design qPCR
assays suitable for a valid quantification, as no suggested
primer combinations resulted in a single specific ampli-
mer. In contrast, the head-to-head-AFS served as a good
template and AFS-qPCR was designed based on the
exact AFS sequence. We quantified MRD in consecutive
BM samples using the 2-ΔΔCt Method as described in the
material and methods section. Strikingly, we found the
detected relative values of leukemic blasts by AFS-qPCR
well comparable to the amounts of leukemic blasts detec-
ted by FACS or routine IgH/TCR-qPCR, respectively for
most of the investigated time points (Figure 2, Additional
file 2: Table S2).
The blast count in the bone marrow at the initial day
of diagnosis was estimated to be 85% by routine FACS
analysis. Relative PCR quantification might be corrected
to this value as described in the material and methods sec-
tion. Corrected data are given in the gray-shaded boxes in
Figure 2 and in separate columns within Additional file 2:
Table S2.
Discussion
Our data show that AFS-PCR is a suitable method for
quantification of MRD of tumor cells with ampGR and
that it is not limited to neuroblastoma with MYCN-amp-
lification. Despite the almost equal quantification results
of AFS-PCR compared to FACS and IgH/TCR-qPCR atherapy estimated by FACS-analysis, routine IgH/TCR-qPCR and
the day of the initial diagnosis, day 15 and day-29 respectively.
the initial diagnosis and the two bone marrow aspirates at day 513 and
marrow aspirates are quantified according to the 2-ΔΔCt calculation
viations are indicated by dots and horizontal bars, respectively.
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29 differ between 5 and 10 fold MRD count. These
differences might be explainable at least in part by the
different quantification procedures. As described, quan-
tification of MRD by AFS-PCR was calculated in rela-
tion to a control gene (Inhibin-Beta-B; INHBB). This is
in contrast to quantification of IgH/TCR-qPCR by com-
paring the PCR values of the subsequent bone marrow
samples in relation to a serial dilution of DNA from
leukemic blasts from the initial diagnosis into control
DNA [6,7]. INHBB was chosen as control gene in this
case of ALL because we have had the information about
a numerically diploid karyotype and exclusion of INHBB
beeing part of a small copy number variation (CNV) by
whole-genome SNP Array in the leukemic blasts. How-
ever, although optimisation of qPCR, conditions for the
relative quantification of the AFS-PCR against INHBB
was performed accurately and although control INHBB-
PCR and AFS-PCR both showed good efficiencies between
10-1 and 10-5 dilution steps (Additional file 3: Figure S1), it
is not possible to exclude, that minor differences in PCR
efficiencies could have influenced the quantification for
day 15 and 29, respectively.
From the days 15 and 29 only a very small amount of
dried bone marrow was obtainable for DNA isolation for
AFS-PCR. Because of the low cell count to these time
points, the whole specimens except a few bone marrow
smears were used for routine diagnostics before. Indica-
ting the low input DNA into AFS-qPCR, the Ct-values
for the INHBB and the AFS-fragment, respectively, were
significantly higher compared to those from the day of
initial diagnosis or day 513 and day 533 (Additional file 4:
Figure S2). The possibility to quantify MRD from such
low amounts of input DNA indicates one great advantage
for the relative quantification to a control gene, as with
AFS-PCR, over the serial dilution method, which depends
on an appointed amount of input DNA. However, with
respect to differences in PCR efficiancies, the very low
amount of input DNA in AFS-qPCR might also have a
part in the lower MRD quantification values calculated
for day 15 and day 29 as compared to IgH/TCR-qPCR.
Another advantage of AFS-PCR is the absolute specifi-
city for the tumor cells in contrast to IgH/TCR-qPCR.
In the latter, the tumor cell specificity varies, dependent
on the degree of difference in the rearranged parts of the
Ig/TCR genes of the leukemic blasts compared to un-
transformed B- and T-cells. It is known that the com-
position of the subpopulations of mononuclear white
blood cells change during therapy, influencing the back-
ground signal and thereby the quantitative range of
IgH/TCR-qPCR, most notably in samples with a low blast
count [7]. In contrast, based on the specific sequences to
both side of the AFS, it was possible to design AFS-
PCR without a significant background for most of theneuroblastoma patients investigated [1] and the head-
to-head junctions of the iAMP21 presented here
(Additional file 4: Figure S2a).
Comparable to amplification of MYCN in childhood
neuroblastomas, iAMP21 including AML1/RUNX1 is dis-
cussed to be an initial event in the development of leu-
kemic blasts comprising this genomic lesion, and no
information exists that AFS change over time within these
cells [8]. It is well known that in some cases, tumors or
leukemias arise out of more than one tumor cell clone.
However, in such cases not only AFS-PCR but all specific
MRD methods are hampered to monitor the course of the
disease exactly, focussing only on one tumor cell clone.
Transferring AFS-PCR to a patient with ALL, we can
give additional proof of concept for the usefulness of tar-
geting junction sites within genomic amplicons for MRD
quantification. Furthermore, by direct comparison to
standard IgH/TCR-qPCR and FACS analysis we can de-
scribe AFS-PCR as highly tumor cell-specific and sensi-
tive for MRD quantification.
A major advantage of AFS-PCR over other methods
for MRD quantification is the possibility of reliably de-
tecting ampGR in primary tumor or bone marrow speci-
mens, even with low tumor cell content. However, given
by the dependency on AFS-sequences, the diagnostic al-
gorithm is limited to patients with malignancies har-
bouring at least one detectable genomic amplification.
Like for all PCR based methods, it might be challenging
in some cases to design proper AFS-qPCR in time, to be
of use in routine MRD diagnostics. Designing AFS-PCR,
it is important to consider all possible orientations of
the subsequent ampGR like head-to-tail, as reported for
all investigated neuroblastomas or head-to-head and
tail-to-tail as shown exemplarily with the ALL-patient
described.
Conclusion
Targeting AFS within iAMP21 in a patient with precur-
sor-B-ALL we can show that quantification of MRD
using AFS-PCR is comparable to other, routinely used
techniques like FISH and Ig/TCR-PCR. The comparison
of a new method with well-established techniques is
an important keystone in a proof of concept and for
MRD diagnostics almost exclusively possible with ALL.
Although, AFS-PCR based on iAMP21 is potentially avail-
able for only 1-2% of patients with ALL, the method could
be taken into account for these patients as alternative
MRD diagnostic, if no or qualitatively poor Ig/TCR-PCRs
are available.
It is without doubt, that, in future, next generation se-
quencing (NGS) of cancer genomes will play a major
role in the diagnostic strategy for cancer patients, as it
provides the possibility not only to identify genomic re-
arrangements on sequence level important for individual
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therapy, but also for use as MRD marker [10]. However,
at present NGS of whole genomes is still expensive and
time-consuming and thus, not suitable for a broad use
in routine diagnostics. Enrichment strategies of prior de-
fined target regions such as ampGR and analysis of mul-
tiple pooled specimens could be an alternative strategy
to make MRD diagnostics available for a bigger number
of patients with different types of cancer and to make it




We studied primary bone marrow specimens from a 9
year and 10 months old female patient with pre-B-ALL.
At time of initial diagnosis the cytogenetic analysis re-
vealed a diploid karyotype (46,XX). Absence of the FISH
signal for the proximal part of one MLL gene sugges-
ted a deletion in this genomic region. Neither a typical
translocation to MLL (MLL/AF4, MLL/AF9, MLL/ENL)
nor BCR/ABL and TEL/AML1 were found. Based upon
cytogenetical findings and adequate response to the in-
duction therapy (MRD values at day 15 below 10-2 and
at day 29 below 10-3), the patient was stratified into the
“standard-low-risk” treatment group and treated accord-
ing to the german COALL-07-03 protocol with informed
consent for therapy and study procedures [11]. (The
study was reviewed by the Ethics committee of the phy-
sicians’ board (City of Hamburg) No. WF-50/08.) During
maintenance therapy the patient’s condition worsened
and rising MRD values were noticed (from day 513 after
initial diagnosis). AML1/RUNX1-amplification was detec-
ted again in recurrent leukemic blasts. Therapy was inten-
sified according to the german ALL-BFM-Rez protocol. In
spite of consequently administered supportive medication,
the patient suffered from a fulminant fungal infection and
died from the disease 6 weeks later.
Fluorescence in-situ hybridisation (FISH)
For FISH analysis specific probes were used for the TEL/
AML1 fusion gene (Vysis LSI ETV6(TEL)RUNX1(AML1)
ES DUALColor Translocation Probe Set), the MLL gene
(Vysis LSI MLL Dual Color, Break Apart Rearrangement
Probe) and the BCR/ABL fusion gene (LSI BCR/ABL ES
Translocation Probe Set) (all probes obtained from Abbott
Laboratories, Abbott Park, IL). FISH was carried out
according to the manufacturer’s instructions. Chromo-
somes were counterstained with 4,6-diamidino-2-pheny-
lindole (DAPI). Digital imaging and documentation were
performed employing a Zeiss Axio Imager.Z2 fluorescence
microscope (ZEISS, Jena, Germany) equipped with an
Isis image analysis system (Metasystems, Altlussheim,
Germany). G-band-like images were generated by software-mediated conversion of DAPI staining into black and white.
For each sample 100 nuclei were analysed.
Fluorescence activated cell sorting (FACS)
Immunophenotyping of diagnostic samples was performed
according to standardized protocols for monoclonal anti-
body staining. Fluorochrome conjugated antibodies were
purchased from Becton Dickinson (BD, San José, CA,
USA): CD45(2D1), CD14(MΦP9), CD10(W8E7), CD20
(L27), CD34(8G12), CD13(L138), CD33(P67.6), CD22
(S-HCL-1), kappa(TB28-2), lambda(1-155-2); Beckmann-
Coulter: CD19(J4.119), CD24(ALB9), TdT(Pool); and
Dako (Denmark): CD79a(HM57), Anti-IgM [F(ab)2](poly-
clonal rabbit). Flow cytometry analyses were performed
within 24 h from collection using a FACS-Calibur (BD)
and the data were processed using Cell Quest pro soft-
ware. CD10 and CD19 costaining of leukemic blasts
(CD10bright/CD19+) of the patient investigated in this
study was used for MRD quantification. For MRD ana-
lysis at least 10.000 cells were acquired for each antibody
combination.
DNA isolation
Isolation of genomic DNA was performed from bone
marrow specimens using the DNA-Blood and Tissue Kit
(QIAGEN). DNA quality and concentration was mea-
sured spectrometrically (Nanodrop, Amersham). After
the beginning of chemotherapy the cell count within the
bone marrow samples decreased rapidly. For the days 15
and 29 all bone marrow specimens had been used for
routine diagnostics (FACS analysis and IgH/TCR-qPCR)
without any material left. The only source for DNA iso-
lation for the two days, were cells scratched from dried
bone marrow smears.
Whole genome microarray analysis
100ng of genomic DNA isolated from bone marrow of
the day of initial diagnosis was hybridized to a Cytoge-
netics Whole-Genome 2.7M Array. The array was pro-
cessed according to the instructions of the manufacturer
using the Cytogenetics Reagent Kit (Affymetrix, Santa
Clara, CA, USA). Chromosome-Analysis-Suite (Version:
CytoB-N1.2.0.232 (r2480) / NetAffx Build 31 (hg19)) was
used for analysis of the data.
High resolution tiling array (HR-TA)
5μg of genomic DNA isolated from bone marrow of the
day of initial diagnosis was hybridized to a Human-CGH-
385K-Chromosome-21 Tiling Array (Roche, NimbleGen)
according to the manufacturer’s conditions. The average
resolution was one DNA-oligonucleotide every 70 bp.
Hybridization of the Tiling Array was performed at Ima-
Genes (Details to the DNA quality criteria and the hybri-
dization methods are available from ImaGenes, Berlin,
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specimen was Cy5-labeled whereas the control DNA was
Cy3-labeled. SignalMap© Software (Ver. 1.9; NimbleGen)
was used for the analysis of the HR-TA data. (Bp-coor-
dinates cited in this study were taken from UCSC Ge-
nome Bioinformatics Database, Assembly February 2009
(NCBI37/hg19)).
Primer design
All primers for standard PCR and RQ-PCR were de-
signed using OLIGO Primer analysis software (Ver. 6.41;




















The PCR for validation of the virtual AFS was performed
under standardized conditions. We used the QIAGEN
HotStarTaq-Plus PCR Mastermix (12.5μl), 200ng DNA, 2
Primer at a final concentration of [1pMol] each, 1.5μl
DMSO (SIGMA) and Aqua-dest. (Braun) ad 25μl. Cycler
conditions were: 5 minutes initial denaturation at 95°C
followed by 38 cycles with 20 seconds at 95°C, 20 seconds
at 57°C and 40 seconds at 72°C. DNA from human pla-
centa tissue served as negative control (cntr.). Electro-
phoresis was performed in 1%-3% agarose gels dependent
on the PCR fragment length. Gels were stained with ethi-
dium bromide and bands were visualized under UV light
(Image Master VDS (Pharmacia)). Bands of estimated
length were excised from the gel and PCR fragments were
isolated using the QIAGEN gel extracting kit following
the manufacturer’s instructions. Each AFS-fragment was
sequenced from both sides using a BigDye Terminator
3.1 Ready Reaction Cycle Seq. Kit (Applied Biosystems)following the manufacturer’s instructions. We used a 16
Capillary Sequencer Genetic Analyzer 3100 from Applied
Biosystems. 250ng of DNA and 10pmol of one primer
were put in one sequencing reaction.Real-time AFS-PCR
Realtime-PCR (RQ-PCR) conditions were: SIGMA SYBR-
GreenJumpStart-Taq Ready Mix (12.5μl), 200ng DNA, 2
Primer at a final concentration of [1pMol] each, 1.5μl
DMSO, 2.5μl and Aqua-dest. ad 25μl. Cycler conditions
were: 5 minutes initial denaturation at 95°C followed by
44 cycles with 20 seconds at 95°C, 20 seconds at 54-58°C
and 40 seconds at 70-72°C (depending on individual pri-
mer binding conditions). All real-time-PCR were per-
formed on a BIORAD iQ5-Cycler. Each real-time PCR,
including the internal control (Inhibin-beta-b (INHBB))
was performed in triplicate. Ct-Values, melt curves and
PCR efficiencies are displayed in Additional file 4: Figure
S2 and Additional file 3: Figure S1 respectively.Ig/TCR based detection of MRD
PCR studies for MRD analysis were performed with IgH
and TCR gene rearrangements as targets. Junctional
regions of clonal products were sequenced directly and
patient specific junctional regions were identified for ge-
neration of allele specific PCR primers. Biclonal or biallelic
products were cloned using the TOPO-TA cloning kit
(Invitrogen) and then processed adequately for generation
of suitable patient specific primers. Subsequently PCR-
MRD targets were tested for specificity and sensitivity to
reach a sensitivity and a quantifiable range of 1 × 10-4 for
at least two targets. Realtime quantitative PCR (RQ-PCR)
was performed and interpreted according to the guidelines
developed within the European Study Group for MRD de-
tection in ALL (ESG-MRD ALL) [7]. In detail, sequence
specific TaqMan probes were used on a LC480 machine
(Roche). Tenfold serial dilutions of diagnostic DNA were
prepared in pooled peripheral blood DNA extracted from
at least five healthy donors. Quantification was perfor-
med using this standard curve and triplicates of follow-
up samples including 500 ng DNA in each reaction. In
the initial diagnostic material the following leukemia
specific targets were detected: the following leukemia
specific targets were detected: Dd2-DD3 (QR 1 × 10-4;
QS 5 × 10-4); Vk1-Kde (QR 5 × 10-4; QS 5 × 10-4);
VγI-Jg1.1; VγI-Jg1.3; Vβ2-Jβ2.3. Targets in bold letters
with a quantifyable range of at least 5 × 10-4 were cho-
sen for quantification of the follow up samples (QR means
the quantifyable range and QS correlates with the sensiti-
vity of each target, both evaluated according the guidelines
of the ESG-MRD-ALL group, as described previously in
more detail [7].
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The relative amounts of AML1/RUNX1 amplified leu-
kemia cells within the different bone marrow samples, in-
vestigated, were calculated using the 2-ΔΔCt method [12].
Therefore, the Ct values of the specific AFS fragments
were normalized to the corresponding Ct values of the
INHBB control PCR fragments. Each resulting ΔCt value
was further normalized to the median ΔCt of the AML1/
RUNX1 amplified leukemia DNA from the initial day of
diagnosis. This calculation resulted in a triplicate of 2-ΔΔCt
values for each specimen, investigated. RQ-PCR data in
Figure 2 present the mean and standard deviation of these
2-ΔΔCt triplicates.
To correct the Ct-value of the specific AFS-PCR frag-
ment of the primary tumor DNA to the tumor cell con-
tent assessed by FACS analysis we used the following
calculation:
AFS Ct correctedð Þ ¼ AFS Ct nativeð Þ þ Log2X :
(X being the relative tumor cell content of the primary
tumor specimen, e.g. 0.8 for 80%). All other Ct values
stayed unchanged. ΔCt values were than calculated in
relation to the corrected ΔCt value of the primary tumor
specimen according to the 2-ΔΔCt method (Data points
in grey shaded boxes in Figure 2 and separate data in
Additional file 2: Table S2).
Additional files
Additional file 1: Table S1. Amplified and deleted chromosomal
regions and the genes covered by these aberrations in the investigated
case of ALL identified by whole genome array (Affymetrix Cytogenetics
Whole-Genome 2.7M Array).
Additional file 2: Table S2. Comparison of the calculated MRD values
estimated by FACS analysis, IgH/TCR-qPCR and AFS-PCR. (a) Blast count
in bone marrow samples from initial diagnosis, day 15 (d15) and day
29 (d29) after the beginning of therapy. (b) Blast count in bone marrow
samples from initial diagnosis and recurrent disease at days 513 (d513)
and 533 (d533).
Additional file 3: Figure S1. Ct-Values (left column) and melting curves
(right column) of the INHBB and the AFS-PCR fragments. (A) First row:
INHBB-PCR and second row: AFS-PCR for detection of MRD values on day
513 (blue) and day 533 (red) including a AFS-negative control DNA
(human placenta) (purple). (B) First row: INHBB-PCR and second row:
AFS-PCR for detection of MRD values on day 15 (orange) and day 29
(light blue).
Additional file 4: Figure S2. PCR efficiencies tested by a 1:10 dilution
series of DNA isolated from bone marrow at time of initial diagnosis.
(A) Ct-values, melting curve and calculated efficiency of the INHBB-PCR.
(B) Ct-values, melting curve and calculated efficiency of the AFS-PCR.
PCR efficiencies were calculated by the BioRad IQ5-Software
(Version 2.1.97.1001).
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